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Abstract
Background: Impulsivity refers to a wide spectrum of actions characterized by quick and nonplanned reactions to external
and internal stimuli, without taking into account the possible negative consequences for the individual or others, and
decision-making is one of the biologically dissociated impulsive behaviors. Changes in impulsivity may be associated with
norepinephrine. Various populations of drug addicts all performed impulsive decision making, which is a key risk factor in
drug dependence and relapse. The present study investigated the effects of clonidine, which decreased norepinephrine
release through presynaptic alpha-2 receptor activation, on the impaired decision-making performance in abstinent heroin
addicts.
Methodology/Principal Findings: Decision-making performance was assessed using the original version of Iowa Gambling
Task (IGT). Both heroin addicts and normal controls were randomly assigned to three groups receiving clonidine, 0, 75 mgo r
150 mg orally under double blind conditions. Psychiatric symptoms, including anxiety, depression and impulsivity, were
rated on standardized scales. Heroin addicts reported higher scores on the Barratt Impulsiveness Scale and exhibited
impaired decision-making on the IGT. A single high-dose of clonidine improved the decision-making performance in heroin
addicts.
Conclusions/Significance: Our results suggest clonidine may have a potential therapeutic role in heroin addicts by
improving the impaired impulsive decision-making. The current findings have important implications for behavioral and
pharmacological interventions targeting decision-making in heroin addiction.
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Introduction
The high propensity to relapse is a hallmark feature of drug
addiction anda main challengefor treatmentstrategies. Impulsivity,
which refers to behavior performed with little or inadequate
forethought, is a key vulnerability factor in drug addiction and risk
factor in relapse [1]. Chronic drug abusers showed elevated scores
on questionnaires measures of impulsivity [2] and impaired
performance on laboratory tasks of impulsivity [3,4].
Impulsivity is a multifactorial construct that can be measured by
tasks such as decision-making, response inhibition, and reflective
impulsivity [5,6]. The Iowa Gambling Task (IGT) [7] was
specifically developed to assess and quantify the decision-making
ability by simulating the real-life decision under ambiguous
conditions [8]. Converging evidence indicates that decision-making
performance is impaired in subjects abusing opiate [9,10], alcohol
[11,12], psychostimulants [11,13], and marijuana [14].
Prefrontal cortical (PFC) network plays an important role in
gating impulsive actions in a variety of behavior tasks [15,16].
Activation of alpha-1 noradrenergic receptor is associated with
short-term changes in PFC function that are consistent with
increased impulsivity [17]. Research in normal subjects found that
laboratory-measured impulsivity was increased by acute adminis-
tration of yohimbine, which augments norepinephrine release by
blocking alpha-2 noradrenergic receptors [18]. Our recent study
has found that the decision-making was impaired in former heroin
addicts up to abstinence for 2 years, and stress can exacerbate an
already existing impairment of decision-making, or unmask a
latent one [19]. Clonidine may decrease norepinephrine release
through presynaptic alpha-2 receptor activation, resulting in
decreased levels of norepinephrine metabolites [20]. However,
there has been no research about the effects of clonidine on
decision-making performance in abstinent heroin addicts.
Thus, our hypothesis was that, at doses that decreased
behavioral arousal or activation, clonidine would improve
decision-making performance in abstinent heroin addicts. Since
150 mg clonidine can suppress blood pressure [21,22], we also
examined the safety and efficacy of this medication at half of the
dose (e.g. 75 mg) in abstinent heroin addicts and hypothesized that
the effect of clinidine may be dose-dependent.
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Fifty-three heroin addicts and 56 normal controls were enrolled
and completed the study. The demographic, substance abuse
characteristics, as well as BDI and HAMA scores of the participants
were summarized in Table 1. One-way ANOVA indicated a
significant effect of Group on self-report ratings of depression on the
BDI-II (F(5,108)=16.38, p,0.05). The analysis revealed that each
subgroup of heroin addicts scored higher on depression compared
with controls (p,0.05). No significant differences in age, education
and anxiety score were found in the three subgroups of heroin
addicts and normal controls. No significant differences were found
in drug use characteristics (duration of heroin use and average dose
abused) across heroin groups.
Heroin addicts reported higher impulsivity scores on the
BIS-11
Table 2 showed self-reported impulsivity on the BIS-11 in
heroin addicts and normal controls. The analysis revealed a
significant effect of Group (F(1,108)=54.288, p,0.05) on self-report
ratings of the BIS-II total score, which meant that heroin addicts
reported higher scores than normal controls. Significant differ-
ences were also found on the subscales motor impulsiveness
(F(1,108)=17.789, p,0.05), attention impulsiveness (F(1,108)=24.77,
p,0.05), and nonplanning impulsiveness (F(1,108)=47.254,
p,0.05). No significant differences were found between the three
subgroups of heroin addicts and normal controls in total scores
and subscale scores of self-reported impulsivity on the BIS-II
(p.0.05).
150 mg clonidine improved the impaired decision-
making in heroin addicts
Fig. 1 showed the change of IGT overall net scores
[(C+D)2(A+B)] in heroin addicts and normal controls. The analysis
revealed that the heroin group tended to select more disadvanta-
geous cards in the IGT at baseline compared with the control group
(F(1,108)=6.09, p,0.05). No difference was found across the three
subgroups in both the control group and heroin group (p.0.05).
The analysis revealed a significant effect of Time (F(1,102)=4.495,
p,0.05), a Time6Group interaction (F(1,102)=4.687, p,0.05), and
a Time6Dose interaction (F(2,102)=2.24, p,0.05). In the heroin
addict groups, two-way ANOVA revealed a significant effect of
Time (F(1,49)=8.17, p,0.05) and a Time6Dose interaction
(F(2,49)=2.68, p,0.05). In within-group comparisons, 150 mg
clonidine, but not 75 mg clonidine or placebo, improved decision-
making performance (p,0.05). In all three subgroups of normal
controls, no significant difference was found between pretreatment
and post-treatment (p.0.05).
150 mg clonidine decreased blood pressure of heroin
addicts
Fig. 2 showed changes in systolic blood pressure (SBP), diastolic
blood pressure (DBP) and heart rate (HR) after clonidine or
Table 1. Demographic and clinical characteristics of participants.
Characteristic Control groups Heroin groups
Placebo
(n=20)
75 mg clonidine
(n=18)
150 mg clonidine
(n=18)
Placebo
(n=17)
75 mg clonidine
(n=18)
150 mg clonidine
(n=18)
Age (years) 29.20(4.72) 31.33 (7.20) 29.83 (5.83) 32.65 (6.71) 32.11 (5.86) 30.5 (6.29)
Education (years) 11.10(2.40) 10.50 (2.12) 11.94 (2.36) 10.06 (2.38) 10.06 (2.34) 9.83 (2.20)
Duration of heroin use
(years)
7.92 (3.45) 7.72 (4.60) 7.00 (4.65)
Dose used (g/d) 0.89 (0.46) 0.85 (0.67) 0.83 (0.45)
Abstinence time (months) 5.39 (2.36) 5.38 (2.35) 5.20 (2.90)
HAMA score 2.80 (1.67) 2.22 (1.63) 2.56 (3.07) 3.71 (1.76) 3.17 (1.65) 3.00 (0.91)
BDI-II score
a 3.10 (3.80) 2.50 (3.20) 3.83 (4.55) 12.9 (5.32) 9.67 (5.11) 10.78 (5.99)
Values are expressed as mean (S.D.). No significant differences were found in age, education, and HAMA score across groups. No significant differences were found for
heroin abuse characteristics (duration, dose, and abstinence time).
aDifference between heroin addicts and normal controls.
doi:10.1371/journal.pone.0029084.t001
Table 2. Self-reported impulsivity on the BIS-II in heroin addicts and normal controls.
Scale/subscale Control groups Heroin groups
Placebo
(n=20)
75 mg clonidine
(n=18)
150 mg clonidine
(n=18)
Placebo
(n=17)
75 mg clonidine
(n=18)
150 mg clonidine
(n=18)
BIS: Attention
a 14.90 (3.24) 14.56 (3.76) 15.33 (3.87) 17.18 (2.70) 17.78 (2.10) 18.67 (2.50)
BIS: Motor
a 21.35 (3.76) 22.22 (3.66) 21.06 (4.33) 25.00 (3.14) 24.28 (2.52) 23.83 (3.24)
BIS: Nonplanning
a 21.60 (4.90) 23.39 (4.22) 22.89 (4.42) 28.88 (4.81) 28.28 (4.42) 28.17 (3.54)
BIS: Total
a 58.25(10.29) 60.17 (7.33) 59.28 (8.45) 71.77 (8.53) 70.33 (6.86) 70.67 (6.62)
Values are expressed as mean (S.D.).
aDifference between heroin addicts and normal controls.
doi:10.1371/journal.pone.0029084.t002
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significant difference in baseline SBP, DBP, or HR between
groups (p.0.05). Both doses of clonidine decreased SBP of heroin
addicts and control subjects (Time effct: (F(3,306)=40.01, p,0.05;
Time6Dose interaction: (F(6,306)=7.17, p,0.05) (Fig. 2A), but not
heart rate (p.0.05; Fig. 2C). 150 mg clonidine significantly
decreased DBP in both control and heroin groups, but 75 mg
clonidine only reduced DBP in the control group (Time effect:
(F(3,309)=42.07, p,0.05), Time6Group interaction (F(3,309)=5.09,
p,0.05), Time6Dose interaction(F(6,309)=8.77, p,0.05))(Fig. 2B).
Discussion
The present placebo-controlled, double-blind study
demonstrated that 150 mg clonidine improved the im-
paired decision-making performance in abstinent hero-
in addicts, which was assessed with the original card
version of the IGT. The impulsive decision-making in heroin
addicts were consistent with previous studies in opiate dependents
using IGT, Game of Dice Task [23] and Cambridge Gambling
Task [24,25]. The lower dose of 75 mg clonidine did not
show the significant effect on the decision-making
ability in heroin abusers. But the pharmacokinetics
study has found the cumulative concentration of chronic
dosing with 75 mg clonidine [26], which suggested this
lower dose of clonidine could be effective to enhance the
decision-making ability.
Studies using neuroimaging and brain lesion technologies have
implicated that prefrontal cortex (PFC), medial frontal cortex and
basal ganglia in controlling impulsive decision making [27].
Various neurotransmitter systems, including norepinephrine,
dopamine and serotonin, in the above brain regions modulated
neural processes underlying the decision-making [28]. Decreased
activation in the specific PFC areas have been found in addicts
[13,29,30].
It has been suggested that stimulation of the alpha-2
adrenoceptor improved PFC function in animals [31,32]. For
example, intra-PFC infusion of the alpha-2 agonist guanfacine in
aged monkeys [20] or rats [33] improved working memory
performance. Conversely, infusion of the alpha-2 antagonist
yohimbine into the PFC in monkeys impaired working memory
performance [34]. Moreover, acute yohimbine increased labora-
tory-measured impulsivity [18,35]. In the present study, the
improvement of decision-making performance in abstinent heroin
addicts by 150 mg clonidine may attribute to presynaptic alpha-2
receptor activation and the subsequent decreased norepinephrine
release in the PFC.
Some limitations of our present study should be noted. First,
retest of IGT may produce a practice effect. However, the
decision-making capacity of drug addicts is similar to that of
patients with ventromedial prefrontal cortex (vmPFC) damage
[36], who did not improve their performance on the gambling task
when tested repeatedly [37]. Moreover, abnormalities in the
vmPFC region were found in cocaine addicts [38]. Second, our
present results did not show the low dose of clonidine
significantly improved the decision-making ability,
which may attribute to the small sample size. The
further research work should enlarge the number of
subjects. The third potential limitation is that the noradrenergic
effects of clonidine were not measured directly in this preliminary
study. However, both the 75 mg and 150 mg clonidine decreased
blood pressure significantly. It has been shown that clonidine
decreased the norepinephrine metabolites and altered working
memory performance [39,40] at doses similar to those used here.
Clonidine could infulence other transmitter systems through
alpha-2 receptors [41,42]. Routine monitoring of blood pressure
was necessary to confirm safety in heroin addicts in future study
because of the significant reduction of blood pressure by clonidine.
In conclusion, we found that abstinent heroin addicts perform
more impulsively, and clonidine may play a potential therapeutic
role in improving the impaired decision-making performance.
These findings have important implications for behavioral and
pharmacological interventions targeting impulsivity in heroin
addiction.
Materials and Methods
The study was approved by the Peking University Research
Ethics Board. All participants provided written informed consent
and received monetary compensation for taking part in the study.
Participants
Eighty-six male abstinent heroin addicts were recruited from the
Yichang Compulsory Rehabilitation Center, Hubei province,
China. Sixty-one normal subjects were recruited through adver-
tisements followed by telephone screening. All subjects were 20 to
40 years old. The study’s procedures and risks were explained and
discussed thoroughly, and written informed consent was obtained
Figure 1. Effects of clonidine on the Iowa Gambling Task in heroin addicts assessed using the original version of IGT net scores
[(C+D)2(A+B)]. Data are expressed as mean 6 SEM. Positive net scores reflect advantageous (non-impaired performance), while negative net scores
reflect disadvantageous (impaired performance). A significant difference was found between heroin addicts and normal controls. A dose of 150 mg
clonidine significantly increased IGT net scores in heroin addicts. *p,0.05, significant difference from placebo subgroup in post hoc t-test.
doi:10.1371/journal.pone.0029084.g001
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addicts were screened using the Structured Clinical Interview for
the Diagnostic and Statistical Manual of Mental Disorders, 4th edition
(DSM-IV) [43] and underwent a thorough interview about their
medical history and a physical examination (electrocardiogram,
blood pressure, heart rate). Exclusion criteria included a history of
head injury or a self-reported history of severe mental illness or
psychosis neurological disorders. Heroin addicts needed to be drug
free for at least 1 month with no current medical illness requiring
pharmacologic treatment or any other substance abuse with the
exception of heroin and nicotine (assessed by urine drug screen and
self-report). They have been treated with methadone for one week,
and the dose regimen was established basing on their body weight,
the doses they took beforeand severity of withdrawal syndrome, etc.
Questionnaires and neuropsychological measures
Demographic characteristics. Demographic characteristics
of the subjects were collected upon arrival, including gender, age,
education years, heroin use time and dose, time of last drug use,
and smoking status.
Hamilton Anxiety Scale. The 14-item Hamilton Anxiety
Scale (HAMA) questionnaire was used to measure anxiety. Items
1–6 and 14 were about psychological anxiety, and items 7–13 were
about somatic anxiety [44].
Beck Depression Inventory. Depressive symptoms were
measured using the 13-item Beck Depression Inventory (BDI).
Each of the 13 items measured the presence and severity of
depressive symptoms by requiring a self-rating from 0 to 3 [45].
Barratt Impulsiveness Scale version-11. The Barratt
Impulsiveness Scale (BIS-11) is a validated questionnaire that
measures different dimensions of impulsivity [46]. The
questionnaire is a 30-item self-report instrument that contains
three subscales: motor impulsiveness (e.g., I am restless at the
theatre or lectures), attention impulsiveness (e.g., I get easily bored
when solving thought problems), and nonplanning impulsiveness
(e.g., I spend or charge more than I earn). The Chinese version of
the BIS-11 has been shown to have good internal consistency and
test-retest reliability [47,48].
Iowa Gambling Task. We used the original card version of
the IGT to evaluate decision-making performance. The task was
administered according to the procedure described by the Iowa
group [7,49]. In the task, the disadvantageous decks of cards yield
higher immediate rewards but unpredictable and larger delayed
punishments, while the advantageous decks provide lower immediate
gains but unexpected and smaller future losses. Quality of decision-
making was measured by the overall net score, which is obtained by
subtracting the number of cards selected from the disadvantageous
decks from the advantageous decks [(C+D)2(A+B)].
Blood pressure and heart rate assessment
Systolic and diastolic blood pressure was measured with a
9062D monitor (Baozhong Biotechnology Company, Beijing,
China). A pulse sensor was attached to the subject’s finger and
connected to an SD-700 monitor to provide a continuous measure
of pulse [50]. Multiple measures of pulse and blood pressure were
monitored for baseline and every 30 min after treatment.
Procedure
Following recruitment, both the normal participants and heroin
addicts were randomly assigned to three groups: placebo, 75 mg
and 150 mg clonidine (Changzhou Pharmaceuticals, Jiangsu,
China) group. The participants and the experimenters were blind
to the study treatment. Each participant attended a testing session
at the clinical laboratory at 8:00 am. Upon arrival, the
experimental procedure was explained to each participant
(Table 3). Following a 15 min adaptation time in which subjects
were instructed to relax, each participant completed the
questionnaires (HAMA, BDI, BIS) and neuropsychological test
(IGT). After baseline testing of blood pressure and heart rate,
subjects received placebo, 75 mg clonidine, or 150 mg clonidine
orally. Clonidine doses were based on previous studies [51,52].
The decision-making test was repeated 90 min later. Blood
pressure and heart rate were monitored every 30 min. Participants
were allowed to leave the laboratory when their systolic blood
pressure and heart rate returned to baseline levels.
Statistical analysis
All data were analyzed with SPSS v. 13.0 (Chicago, IL, USA).
Demographic characteristics (i.e., age, years of education, duration
Figure 2. Effects of clonidine on blood pressure and heart rate
in heroin addicts. (A) Systolic blood pressure. Treatment with 75 mg
and 150 mg clonidine significantly decreased systolic blood pressure at
90 min in both heroin addicts and normal controls. (B) Diastolic blood
pressure. Treatment with 150 mg clonidine significantly decreased
diastolic blood pressure at 90 min in both heroin addicts and normal
controls. Treatment with 75 mg clonidine significantly decreased
diastolic blood pressure at 90 min in normal controls. (C) Heart rate.
No effect of clonidine was found on heart rate. *p,0.05, compared with
baseline in post hoc t-test. Data are expressed as mean 6 SEM.
doi:10.1371/journal.pone.0029084.g002
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psychiatric symptoms, including anxiety, depression, and impul-
sivity among groups were compared using one-way analysis of
variance (ANOVA). Iowa Gambling Task scores were analyzed by
three-way ANOVA with the between-subjects factors of Group
(heroin group vs. control group) and Dose (placebo, 75 mg, and
150 mg clonidine) and the within-subjects factor of Time
(pretreatment vs. post-treatment). In the heroin addict groups,
IGT scores were analyzed by two-way ANOVA with the between-
subjects factor of Dose (placebo, 75 mg, and 150 mg clonidine) and
the within-subjects factor of Time (pretreatment vs. post-
treatment). Repeated-measures ANOVA with the between-
subjects factors of Group (heroin group vs. control group) and
Dose (placebo, 75 mg, and 150 mg clonidine) and the within-
subjects factor of Time (0, 30, 60, and 90 min) were used to
analyze systolic blood pressure, diastolic blood pressure and heart
rate. Post hoc pairwise comparisons were conducted with Fisher’s
Least Significant Difference (LSD) test. Values of p,0.05 were
considered statistically significant. Means are given with standard
deviations.
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